GEO Investing

The first theme is that of Morning Management Briefings that serve to inform us, and therefore you, about current events pertaining to the companies we follow, especially at times surrounding important events, like earnings. You might already be aware that we conducted a few short conversations, the last 2 on 2/22/2022 being with Jerry Fleming, CEO of Altigen Communications Inc (OTC:ATGN) and Jad Fakhry who sits on Stephan Co (OTC:SPCO)’s Board of Directors, and the first a week before that with Doug Gaylor, President & COO of Crexendo, Inc. (NASDAQ:CXDO) . Below are a few clips from the briefings, 1 from the talk with ATGN and 1 from SPCO that you might find informative.

As you know, the company’s President and COO, Doug Gaylor, participated in our new Management Morning Briefing service on March 16, 2022. CXDO was the second company to have been featured in such a manner. Altigen Communications Inc (OTC:ATGN) is next in line, this week.

Even though the stock isn’t performing commensurate with the strong sentiment being conveyed by the company, the narrative has not changed and is still echoed in the briefing.

A key piece of input we wanted to get clarity on from Doug was how he felt about the competitive landscape of the UCaaS industry, especially in light of Ringcentral, Inc. (NYSE:RNG) 36% year to date decline in stock price. More specifically, is the decline in RNG’s price a warning that the industry growth outlook may be changing? We also wanted to get Doug’s opinion on how CXDO is positioned to compete as Microsoft begins to aggressively roll out its UCaaS product offerings. It’s worth noting that CXDO is now selling at a P/S of 2.2 on current 2022 revenue estimates.

Graphite Bio agrees repairing autologous hematopoietic stem cells (HSCs) through CRISPR is difficult. But the company claims its targeted gene integration platform and manufacturing technologies considerably upgrade the original CRISPR/Cas9 approach. Improved targeting can lead to higher rates of homology directed repair (HDR) in genes, which assures efficient incorporation of repaired genes into the genome, according to the company. SanaCurrents assigns a speculative rating Graphite will report positive initial proof-of-concept data from its phase I/II trial results testing its lead drug GPH101 in SCD.

In March, we’ve already received two premium member contributions – one from Andrew Ing (@AndrewIng8) on a stock based in Australia, which is a first for our community, and another from Tim Heitman (@Investing501), who regularly published articles to GeoInvesting in 2021. We’d like to extend a thank you to them for choosing GeoInvesting as the platform to share their ideas for all of us to appreciate.